Paratek Pharmaceuticals (PRTK) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a hold rating to a sell rating in a research note issued to investors on Wednesday.
According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
A number of other equities research analysts have also recently issued reports on the stock. ValuEngine cut shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, January 2nd. Canaccord Genuity began coverage on shares of Paratek Pharmaceuticals in a report on Wednesday, January 2nd. They issued a buy rating and a $14.00 target price on the stock. LADENBURG THALM/SH SH reaffirmed a buy rating and issued a $18.00 target price on shares of Paratek Pharmaceuticals in a report on Tuesday, December 18th. HC Wainwright lowered their price target on shares of Paratek Pharmaceuticals from $55.00 to $22.00 and set a buy rating on the stock in a report on Friday, November 23rd. Finally, BidaskClub cut shares of Paratek Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, October 12th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. Paratek Pharmaceuticals has a consensus rating of Hold and an average price target of $23.44.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.16). The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $5.89 million. Paratek Pharmaceuticals had a negative net margin of 2,155.03% and a negative return on equity of 132.55%. Sell-side analysts predict that Paratek Pharmaceuticals will post -3.51 EPS for the current fiscal year.
In other Paratek Pharmaceuticals news, Chairman Michael Bigham sold 6,300 shares of the stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $8.96, for a total value of $56,448.00. Following the transaction, the chairman now directly owns 271,167 shares of the company’s stock, valued at approximately $2,429,656.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas John Dietz sold 9,330 shares of the stock in a transaction dated Friday, December 21st. The shares were sold at an average price of $5.01, for a total transaction of $46,743.30. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $37,575. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,248 shares of company stock worth $377,411. Insiders own 6.20% of the company’s stock.
Several large investors have recently made changes to their positions in PRTK. National Asset Management Inc. acquired a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth approximately $117,000. Metropolitan Life Insurance Co. NY grew its position in shares of Paratek Pharmaceuticals by 81.4% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 6,625 shares in the last quarter. MetLife Investment Advisors LLC grew its position in shares of Paratek Pharmaceuticals by 57.1% during the 2nd quarter. MetLife Investment Advisors LLC now owns 16,222 shares of the specialty pharmaceutical company’s stock worth $165,000 after purchasing an additional 5,895 shares in the last quarter. Rhumbline Advisers grew its position in shares of Paratek Pharmaceuticals by 26.8% during the 2nd quarter. Rhumbline Advisers now owns 29,515 shares of the specialty pharmaceutical company’s stock worth $301,000 after purchasing an additional 6,240 shares in the last quarter. Finally, Alps Advisors Inc. grew its position in shares of Paratek Pharmaceuticals by 22.5% during the 3rd quarter. Alps Advisors Inc. now owns 56,149 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 10,296 shares in the last quarter. Hedge funds and other institutional investors own 74.75% of the company’s stock.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Further Reading: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.